Role of VEPs in Early Diagnosis of Central Neuropathy in Type 2 Diabetes Mellitus

Aparna, A

doi:10.5958/0976-5506.2016.00210.2

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes mellitus (DM) is considered a global epidemic, and constitutes one of the most important health care challenges [1] , as chronic high blood sugar causes damage to multiple organs, especially the eyes, kidneys, nerves, heart and blood vessels [2] .…”

Section: Introductionmentioning

confidence: 99%

Study of the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with diabetes mellitus type 2

Sabbagh¹

2022

Journal of Medical and Pharmaceutical Sciences

View full text Add to dashboard Cite

Objective: To evaluate the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with Diabetes Mellitus type 2. Methods: the study was conducted on 73 eyes of 73 patients who had type 2 diabetes for 5 years or more. The pupil diameter (PD) was measured in the both eyes without dilation using an Autorefractokeratometer (Grand Seiko\GR- 3500 Ka), then the pupils were dilated in the both eyes using topical Tropicamide 1%. A second measurement of (PD) was taken after dilating using the same device. Topical Nepafenac 0.1% were prescribed 3 times a day for 3 days in the right eye. During the review, after 3 days, the pupils were dilated using topical Tropicamide 1%. A third measurement of the (PD) of the both eyes was taken after dilation using the same device. The efficacy of Nepafenac 0.1% was evaluated by determining the increase in (PD) in the eye that received topical Nepafenac 0.1% and comparing it with the other eye that did not receive. Results: The mean diameter of the pupil in the right eye after dilation was 4.68±0.8 mm and in the left eye was 4.67±0.7 mm (P=0.8). After applying Nepafenac 0.1% topically 3 times a day in the right eye for 3 days, the mean diameter of the pupil in the right eye after dilation was 6.50 ± 0.9 mm and in the left eye 5.10± 0.08 mm (P=0.001). The change in the mean diameter of the pupil in the right eye was 1.82 ± 0.7 mm, and in the left eye was 0.43 ± 0.6 mm. Conclusion: Topical application of Nepafenac 0.1% showed an increase in pupillary diameter after dilation with Tropicamide 1% in patients with type 2 diabetes mellitus.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with diabetes mellitus type 2

Sabbagh¹

2022

Journal of Medical and Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…Diabetes mellitus (DM) is recognized as the global epidemic, presently one of the most important challenges in healthcare [1]. Chronic hyperglycemia of diabetes is associated with long term damage, dysfunction and the failure of various organs, especially the eyes, kidneys, nerves, the heart and the blood vessels [2]. An estimated 463.0 million adults aged 20-79 years worldwide (9.3% of all adults in this age group) have diabetes.…”

Section: Introductionmentioning

confidence: 99%

Electroretinogram and Visual Evoked Potentials in Patients with Type ll Diabetes Mellitus

Saadoun¹,

Rajab²,

Yousef³

2020

AJBLS

View full text Add to dashboard Cite

Background: Retinopathy is a severe and common complication of diabetes. The pathology seems to be characterized not only by the involvement of retinal micro vessels but also by a real neuropathy. Before the onset of micro vascular lesions, the retina of the eye undergoes subtle functional changes that are not detectable by fundus photography. Electrophysiological investigations allow a more detailed study of the visual function. These techniques are safe, repeatable, quick, and objective. Objective: To study pattern electroretinogram (PERG) and pattern reversal visual evoked potentials (PRVEP) in type 2 diabetic patients without diabetic retinopathy (DR) or with mild non-proliferative DR (mNPDR) to detect changes by comparing with those of healthy control. And to assess the correlation of the parameters with diabetes duration and the level of Glycosylated Haemoglobin A1c (HbA1c). Materials and Methods: It was a cross-sectional study, included two groups (diabetic patients and the healthy). Age range was preset at 40-65 years. For all the participants, a detailed clinical history was collected, a comprehensive ophthalmic examination and thorough blood investigations were performed, then {PRVEP (60', 15'), PERG} were recorded and (waveform, peak time, amplitude) of tests components were analyzed. Results: Mean (P100, N135) peak times of PRVEP were statistically significantly delayed in (50) eyes of type 2 diabetics without DR when compared to (36) eyes of control (p-value<0.01), abnormalities in waveforms like (double peaks, broad peak) were also observed in diabetics. There were alterations in other parameters (amplitudes of PRVEP, peak times and amplitudes of PERG) but the changes were not statistically significant. No statistically significant changes were found in (6) eyes of diabetic patients with mNPDR. No statistically significant correlation was obtained between diabetes duration or the level of HbA1c and delay of peak times or reduce amplitudes in patients. Conclusions: Electrophysiological tests are sensitive and useful investigations for the early identification of visual dysfunctions before the development of overt retinopathy in type 2 diabetics. PRVEP is more sensitive than PERG to monitor alterations and it may be sufficient to screen the patients in this stage.

show abstract

Role of VEPs in Early Diagnosis of Central Neuropathy in Type 2 Diabetes Mellitus

Cited by 2 publications

References 0 publications

Study of the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with diabetes mellitus type 2

Study of the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with diabetes mellitus type 2

Electroretinogram and Visual Evoked Potentials in Patients with Type ll Diabetes Mellitus

Contact Info

Product

Resources

About